The world's first oral targeted therapy for HER2-mutated advanced non-small cell lung cancer has been approved in China.

On August 29, Boehringer Ingelheim and Chinese Biopharmaceutical jointly announced that the Zelinib tablets, which they are jointly promoting in mainland China, have been officially approved by the China National Medical Products Administration for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer adult patients with HER2 activating mutations who have received at least one systemic treatment in the past. This is the world's first and currently the only orally available HER2 tyrosine kinase inhibitor approved.